Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GALR3 | O60755 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10937368 | 0.81 | ALDH1A1 (0.50) | TSHRALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL47823 | 0.80 | — | — | |
| SCHEMBL9761916 | 0.78 | — | — | |
| SCHEMBL609519 | 0.75 | TSHR (0.38) | TSHRALDH1A1 | |
| SCHEMBL222173 | 0.75 | TSHR (0.38) | TSHRSMN1; SMN2 | |
| SCHEMBL11782178 | 0.73 | TSHR (0.36) | TSHR | |
| SCHEMBL10620706 | 0.71 | TSHR (0.35) | TSHR | |
| SCHEMBL3359533 | 0.71 | TSHR (0.35) | TSHR | |
| SCHEMBL2991504 | 0.71 | TSHR (0.35) | TSHR | |
| SCHEMBL9367326 | 0.71 | TSHR (0.35) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024022262-A1 | SALT OF ENDOTHELIN A (ETA) RECEPTOR ANTAGONIST COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 深圳信立泰药业股份有限公司 | 2024-02-01 | — | — | WO | disclosed |
| WO-2023208108-A1 | COMPOUND FOR REDUCING URIC ACID | 江苏新元素医药科技有限公司 | 2023-11-02 | — | — | WO | disclosed |
| WO-2023208103-A1 | COMPOUND CAPABLE OF BEING USED FOR GOUT | 江苏新元素医药科技有限公司 | 2023-11-02 | — | — | WO | disclosed |
| EP-3486242-B1 | OXOPICOLINAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO (CN) | 2021-12-08 | — | — | EP | disclosed |
| CN-113683614-A | Fused tricyclic pyridazinone compounds for the treatment of orthomyxoviral infections | 诺华股份有限公司 | 2021-11-23 | — | — | CN | disclosed |
| CN-109863151-B | Fused tricyclic pyridazinone compounds for the treatment of orthomyxoviral infections | 诺华股份有限公司 | 2021-09-10 | — | — | CN | disclosed |
| US-11084808-B2 | Oxopicolinamide derivative, preparation method therefor and pharmaceutical use thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2021-08-10 | — | — | US | disclosed |
| CN-112969687-A | Quinoline derivatives as alpha 4 beta 7 integrin inhibitors | 吉利德科学公司 | 2021-06-15 | — | — | CN | disclosed |
| CN-112154145-A | Piperazine azaspiro derivatives | 辉瑞大药厂 | 2020-12-29 | — | — | CN | disclosed |
| US-20200199115-A1 | OXOPICOLINAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2020-06-25 | — | — | US | disclosed |
| US-20020143043-A1 | Substituted imidazolidine derivatives, their preparation, their use and pharmaceutical preparations including them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-10-03 | — | — | US | disclosed |
| US-6331552-B1 | THERAPY AND PROPHYLAXIS OF INFLAMMATORY DISORDERS, FOR EXAMPLE OF RHEUMATOID ARTHRITIS, OR OF ALLERGIC DISORDERS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-12-18 | — | — | US | disclosed |
| US-5688946-A | DIPEPTIDES FOR HYPOTENSIVE AGENTS AND CARDIOVASCULAR DISORDERS | HOFFMANN LA ROCHE INC. (US) | 1997-11-18 | — | — | US | disclosed |
| US-5587374-A | BACTERICIDES TREATING INFECTIONS | GLAXO SPA (IT) | 1996-12-24 | — | — | US | disclosed |
| EP-0495953-B1 | 10-(1-Hydroxyethyl)-11-oxo-1-azatricyclo[7.2.0.0(3,8)]undec-2-ene-2-carboxylic acid esters and a process for preparing thereof | GLAXO SPA (IT) | 1994-06-08 | — | — | EP | disclosed |
| EP-0236231-B1 | Novel cephem compounds | MEIJI SEIKA KAISHA (JP) | 1994-05-04 | — | — | EP | disclosed |
| EP-0495953-A1 | 10-(1-Hydoxyethyl)-11-oxo-1-azatricyclo(7.2.0.0(3,8)undec-2-ene-2-carboxylic acid esters and a process for preparing thereof. | GLAXO SPA (IT) | 1992-07-29 | — | — | EP | disclosed |
| WO-1992003437-A1 | 10(1-HYDROXYETHYL)-11-OXO-1-AZATRICYCLO[7.2.0.0.3.8]UNDEC-2-ENE-2-CARBOXYLIC ACID ESTERS AND A PROCESS FOR PREPARING THEREOF | GLAXO S.P.A. (IT) | 1992-03-05 | — | — | WO | disclosed |
| US-4918068-A | ACTIVE AGAINST GRAM POSITIVE BACTERIA | MEIJI SEIKA KAISHA, LTD. (JP) | 1990-04-17 | — | — | US | disclosed |
| EP-0236231-A2 | Novel cephem compounds | MEIJI SEIKA KAISHA LTD. (JP) | 1987-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143043-A1 | Substituted imidazolidine derivatives, their preparation, their use and pharmaceutical preparations including them | VCAM1, ITGA1, ITGA4 | TSHR 413/4885CHRM2 602/4885CHRM4 573/4885 |
| US-20200199115-A1 | OXOPICOLINAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | F11, F2, F7 | TSHR 4646/4885CHRM2 4825/4885CHRM4 4803/4885 |
| US-11084808-B2 | Oxopicolinamide derivative, preparation method therefor and pharmaceutical use thereof | F11, F2, F7 | TSHR 4617/4885CHRM2 4863/4885CHRM4 4843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.